Waterdrop Inc. Announces Second Quarter 2025 Unaudited Financial Results and a Cash Dividend
Financial and Operational Highlights for the Second Quarter of 2025
- Further improvement in profitability: In the second quarter of 2025, net profit attributable to our ordinary shareholders reached
RMB140.2 million (US$19.6 million ), representing a solid increase of 58.7% year-over-year. We continued to generate positive operating cash flow during the second quarter of 2025. - Significant growth in insurance premiums: The first-year premiums ("FYP") generated through our insurance business reached
RMB3,204.3 million (US$447.3 million ) during the second quarter of 2025, representing an increase of 80.2% year-over-year. Net operating revenue wasRMB838.0 million (US$117.0 million ), representing an increase of 23.9% year-over-year. - Medical crowdfunding coverage: As of
June 30, 2025 , around 480 million people had cumulatively donated an aggregate ofRMB70.0 billion to 3.54 million patients through Waterdrop Medical Crowdfunding. - Patient recruitment performance: As of
June 30, 2025 , the Company had cumulatively enrolled 12,216 patients into 1,385 clinical trial programs through the E-Find Platform.
Mr. Peng Shen, Founder, Chairman, and Chief Executive Officer of
The insurance business delivered an exceptional quarter. Year-over-year, FYP grew by 95.0% in short-term policies and 45.4% in long-term ones. This robust growth drove significant increases in both segment revenue and operating profit, expanding the operating margin by 2 percentage points. These results underscore the effectiveness of our strategic focus on enhanced user acquisition, accelerated product iteration, and the implementation of AI-enhanced services.
Our "Waterdrop Guardian" AI Application Suite constantly evolves, either interacting directly with end users or empowering our online consultants behind the scenes. Premiums facilitated by 'AI Medical Insurance Expert' climbed 155% compared to the previous quarter. 'AI Customer Service Agent' resolved 60% of inquiries on first contact, enhancing user experience. 'Life Planner Copilot' has handled 300,000 insurance product-related consultations from our online consultants, driving a double-digit productivity growth in Q2. We recently launched 'KEYI.AI', a real-time AI underwriting assistant for consultants, with plans to extend its availability to industry partners later this year.
On a separate note, we completed the acquisition of the remaining equity in Shenlanbao in June and anticipate further accelerating synergies.
During the second quarter, Waterdrop Medical Crowdfunding upgraded its risk assessment capabilities. A large-language-model ("LLM") engine now scans every campaign's content, comments and hidden clues, feeding insights into a smart matrix that tracks 15 high-risk scenarios, and refines itself to identify risks more accurately. Additionally, this quarter we partnered with
In this quarter, E-Find Platform expanded its collaboration to 198 pharmaceutical and contract research organizations. Meanwhile, we initiated services for 114 new programs. The number of patients enrolled also reached a historic high, with 999 patients enrolled in the second quarter of 2025, representing a 34.2% year-over-year revenue growth.
With a commitment to superior shareholder returns, we are pleased to announce that our board of directors of the Company (the "Board") has recently approved an enhanced cash dividend of
Looking ahead to the second half of 2025, we will strive to deliver both top-line and bottom-line growth. We believe that tech-driven innovation is the core strategy and source of business excellence, and look forward to delivering a compelling success story, as well as value to our users, partners and shareholders."
Financial Results for the Second Quarter of 202 5
Operating revenue, net
Net operating revenue for the second quarter of 2025 increased by 23.9% year-over-year to
- Insurance-related income includes insurance brokerage income and technical service income. Insurance brokerage income represents brokerage commissions earned from insurance companies. Technical service income is derived from providing technical services including risk control technical service, user analytics and intelligent recommendation service, customer relationship maintenance, customer complaint management, claim review, and user referral services, among other things, to insurance companies, insurance brokers, and agency companies. Our insurance-related income amounted to
RMB738.6 million (US$103.1 million ) in the second quarter of 2025, representing an increase of 28.7% year-over-year fromRMB573.8 million for the second quarter of 2024, which was mainly due to the increase in technical service income. On a quarter-over-quarter basis, insurance-related income increased by 12.2%. - Crowdfunding service fees represent the service income earned when patients successfully withdraw the proceeds from their crowdfunding campaigns. Our role is to operate the Waterdrop Medical Crowdfunding platform to provide crowdfunding related services through the internet, enabling patients with significant medical bills to seek help from caring hearts through technology (the "medical crowdfunding services"). Our medical crowdfunding services generally consist of providing technical and internet support, managing, reviewing and supervising the crowdfunding campaigns, providing comprehensive risk management and anti-fraud measures, and facilitating the collection and transfer of the funds. For the second quarter of 2025, we generated
RMB67 .4 million (US$9 .4 million) in service fees, representing a slight decrease of 2.7% year-over-year fromRMB69 .3 million for the second quarter of 2024. On a quarter-over-quarter basis, crowdfunding service fees remained stable. - Digital clinical trial solution income represents the service income earned from our customers mainly including biopharmaceutical companies and leading biotechnology companies. We match qualified and suitable patients for enrollment in clinical trials for our customers and generate digital clinical trial solution revenue for successful matches and we typically charge our customers a fixed unit price per successful match. For the second quarter of 2025, our digital clinical trial solution income amounted to
RMB27.7 million (US$3.9 million ), representing an increase of 34.2% fromRMB20.7 million in the same period of 2024. On a quarter-over-quarter basis, digital clinical trial solution income increased by 20.6%.
Operating costs and expenses
Operating costs and expenses increased by 18.7% year-over-year to
- Operating costs increased by 30.5% year over year to
RMB416.5 million (US$58.1 million ) for the second quarter of 2025, as compared withRMB319.1 million for the second quarter of 2024, which was primarily driven by (i) an increase ofRMB73.4 million in costs of referral and service fees, (ii) an increase ofRMB10.8 million in the costs for the crowdfunding consultants team, and (iii) an increase ofRMB7.0 million in personnel costs. On a quarter-over-quarter basis, operating costs increased by 11.3% fromRMB374.2 million , primarily due to (i) an increase ofRMB25.0 million in costs of referral and service fees, and (ii) an increase ofRMB7.3 million in personnel costs. - Sales and marketing expenses increased by 26.3% year-over-year to
RMB198.8 million (US$27.7 million ) for the second quarter of 2025, as compared withRMB157.4 million for the same quarter of 2024. The increase was primarily due to an increase ofRMB44.3 million in marketing expenses for third-party traffic channels. On a quarter-over-quarter basis, sales and marketing expenses increased by 15.3% fromRMB172.4 million , primarily due to an increase ofRMB25.4 million in marketing expenses for third-party traffic channels. - General and administrative expenses decreased by 21.9% year-over-year to
RMB73.4 million (US$10.2 million ) for the second quarter of 2025, compared withRMB94.0 million for the same quarter of 2024. The year-over-year variance was due to (i) a decrease ofRMB13.4 million in allowance for credit losses, and (ii) a decrease ofRMB6.0 million in professional service fees. On a quarter-over-quarter basis, general and administrative expenses decreased by 2.1% fromRMB74.9 million , due to our effective cost control measures. - Research and development expenses remained stable at
RMB51.9 million (US$7.3 million ) for the second quarter of 2025, maintaining nearly the same level asRMB53.3 million for the same period of 2024. On a quarter-over-quarter basis, research and development expenses decreased by 7.6% fromRMB56.2 million . The decrease was primarily due to a decrease ofRMB3.8 million in personnel costs and share-based compensation expenses.
Operating
profit
for the second quarter of 2025 was
Interest income
for the second quarter of 2025 was
Income tax
benefit
for the second quarter of 2025 was
Net profit
attributable to the Company's ordinary shareholders
for the second quarter of 2025 was
Adjusted net profit
attributable to the Company's ordinary shareholders (non-GAAP(1))
for the second quarter of 2025 was
Cash position(2)
As of
(1) See the sections entitled "Non-GAAP Financial Measure" and "Reconciliations of GAAP and Non-GAAP Results" for more information about the non-GAAP |
(2) Cash position includes cash and cash equivalents, short-term investments, and long-term debt investments included in long-term investments. |
Share Repurchase Programs
Pursuant to the share repurchase programs launched in
Our Board has approved a new share repurchase program whereby the Company is authorized to repurchase its own ordinary shares in the form of American depository shares with an aggregate value of up to US$50 million during the 12-month period through September 9, 2026. The Company expects to fund the repurchase from its existing cash balance. The Company's proposed repurchases may be made from time to time in the open market at prevailing market prices, in privately negotiated transactions, in block trades and/or through other legally permissible means, depending on market conditions and in accordance with applicable rules and regulations. The timing and dollar amount of repurchase transactions will be subject to the requirements of the Securities and Exchange Commission Rule 10b-18 and/or Rule 10b5-1. The Board will review the share repurchase program periodically, and may authorize adjustment to its terms and size or suspend or discontinue the program.
Cash Dividend
The Board has approved a cash dividend of US$0.03 per ADS or US$0.003 per ordinary share, for a total amount of approximately US$10.9 million, to shareholders of record as of the close of business on
Supplemental Information
We organize and report our business in the following operating segments:
- Insurance, which mainly includes insurance brokerage service and technical service;
- Crowdfunding, which mainly includes crowdfunding service; and
- Others, which do not individually or in the aggregate meet the quantitative and qualitative thresholds to be individually reportable and are aggregated.
The table below sets forth the segment operating results, with three-month and six-month ended
|
|
For the Three Months Ended |
|
For the Six Months Ended |
||||||||||
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
RMB |
|
RMB |
|
RMB |
|
USD |
|
RMB |
|
RMB |
|
USD |
|
|
(All amounts in thousands) |
|
|
|
|
|
|||||||
Operating revenue, net |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Insurance |
|
573,832 |
|
657,988 |
|
738,561 |
|
103,099 |
|
1,180,609 |
|
1,396,549 |
|
194,951 |
Crowdfunding |
|
69,323 |
|
67,131 |
|
67,419 |
|
9,411 |
|
136,673 |
|
134,550 |
|
18,782 |
Others |
|
33,001 |
|
28,575 |
|
31,979 |
|
4,465 |
|
63,574 |
|
60,554 |
|
8,453 |
Total consolidated operating revenue, net |
|
676,156 |
|
753,694 |
|
837,959 |
|
116,975 |
|
1,380,856 |
|
1,591,653 |
|
222,186 |
Operating costs and expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Insurance |
|
(450,877) |
|
(506,575) |
|
(567,642) |
|
(79,239) |
|
(928,491) |
|
(1,074,217) |
|
(149,955) |
Crowdfunding |
|
(92,259) |
|
(97,299) |
|
(99,519) |
|
(13,892) |
|
(191,846) |
|
(196,818) |
|
(27,475) |
Others |
|
(60,451) |
|
(54,000) |
|
(58,620) |
|
(8,183) |
|
(122,456) |
|
(112,620) |
|
(15,721) |
Operating profit/(loss) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Insurance |
|
122,955 |
|
151,413 |
|
170,919 |
|
23,860 |
|
252,118 |
|
322,332 |
|
44,996 |
Crowdfunding |
|
(22,936) |
|
(30,168) |
|
(32,100) |
|
(4,481) |
|
(55,173) |
|
(62,268) |
|
(8,693) |
Others |
|
(27,450) |
|
(25,425) |
|
(26,641) |
|
(3,718) |
|
(58,882) |
|
(52,066) |
|
(7,268) |
Total segment operating profit |
|
72,569 |
|
95,820 |
|
112,178 |
|
15,661 |
|
138,063 |
|
207,998 |
|
29,035 |
Unallocated items* |
|
(20,205) |
|
(19,927) |
|
(14,842) |
|
(2,072) |
|
(39,335) |
|
(34,769) |
|
(4,854) |
Total consolidated operating profit |
|
52,364 |
|
75,893 |
|
97,336 |
|
13,589 |
|
98,728 |
|
173,229 |
|
24,181 |
Total other income |
|
38,366 |
|
41,690 |
|
40,032 |
|
5,589 |
|
81,147 |
|
81,722 |
|
11,408 |
Consolidated profit before income tax |
|
90,730 |
|
117,583 |
|
137,368 |
|
19,178 |
|
179,875 |
|
254,951 |
|
35,589 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* The share-based compensation represents unallocated items in the segment information because our management does |
In order to strengthen synergies between the Group and Shenlanbao, the Group entered into a new share purchase agreement with all non-controlling shareholders of Shenlanbao to acquire all remaining equity interests in Shenlanbao. All of the closing conditions included in the new agreement had been met as of
With full ownership, the Group can drive stronger strategic synergy. This acquisition also enables us to strengthen our service differentiation and extend technology deployment. By leveraging the Group's industry insights while preserving Shenlanbao's operational independence, we will unlock new growth opportunities for the enlarged entity.
Exchange Rate
This announcement contains translations of certain RMB amounts into
Non-GAAP Financial Measure
The Company uses non-GAAP financial measure, adjusted net profit attributable to our ordinary shareholders, in evaluating the Company's operating results and for financial and operational decision-making purposes. Adjusted net profit attributable to our ordinary shareholders represents net profit attributable to our ordinary shareholders excluding share-based compensation expense attributable to our ordinary shareholders and foreign currency exchange gain or losses. Such adjustments have no impact on income tax.
The non-GAAP financial measure is not presented in accordance with
The Company mitigates these limitations by reconciling the non-GAAP financial measure to the most comparable
For more information on the non-GAAP financial measure, please see the table captioned "Reconciliation of GAAP and Non-GAAP Results" set forth at the end of this press release.
Safe Harbor Statement
This press release contains statements that may constitute "forward-looking" statements pursuant to the "safe harbor" provisions of the
Conference Call Information
International: |
1-412-317-6061 |
United States Toll Free: |
1-888-317-6003 |
Hong Kong Toll Free: |
800-963976 |
|
852-58081995 |
Mainland |
4001-206115 |
Chinese Line (Mandarin) Entry Number: |
0088782 |
English Interpretation Line (Listen-only Mode) Entry Number: |
7013962 |
Participants can choose between the Chinese and the English interpretation lines. Please note that the English interpretation option will be in listen-only mode. Please dial in 15 minutes before the call is scheduled to begin and provide the Elite Entry Number to join the call.
Telephone replays will be accessible two hours after the conclusion of the conference call through
United States Toll Free: |
1-877-344-7529 |
International: |
1-412-317-0088 |
Chinese Line Access Code: |
4409082 |
English Interpretation Line Access Code: |
3334217 |
A live and archived webcast of the conference call will also be available at the Company's investor relations website at http://ir.waterdrop-inc.com/.
About
For investor inquiries, please contact
IR@shuidi-inc.com
|
|||||
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS |
|||||
(All amounts in thousands, unless otherwise noted) |
|||||
|
|||||
|
As of |
||||
|
|
|
|
||
|
RMB |
|
RMB |
|
USD |
Assets |
|
|
|
|
|
Current assets |
|
|
|
|
|
Cash and cash equivalents |
986,323 |
|
722,006 |
|
100,788 |
Restricted cash |
520,588 |
|
637,817 |
|
89,036 |
Short-term investments |
1,612,619 |
|
942,293 |
|
131,539 |
Accounts receivable, net |
716,206 |
|
838,571 |
|
117,060 |
Current contract assets |
619,436 |
|
679,254 |
|
94,820 |
Amount due from related parties |
257 |
|
315 |
|
44 |
Prepaid expense and other assets |
182,641 |
|
202,457 |
|
28,263 |
Total current assets |
4,638,070 |
|
4,022,713 |
|
561,550 |
Non-current assets |
|
|
|
|
|
Non-current contract assets |
153,749 |
|
195,902 |
|
27,347 |
Property, equipment and software, net |
240,024 |
|
246,610 |
|
34,425 |
Intangible assets, net |
153,011 |
|
152,946 |
|
21,350 |
Long-term investments |
1,114,160 |
|
1,786,589 |
|
249,398 |
Right of use assets, net |
46,872 |
|
17,185 |
|
2,399 |
Deferred tax assets |
27,028 |
|
20,332 |
|
2,838 |
|
80,751 |
|
80,751 |
|
11,272 |
Total non-current assets |
1,815,595 |
|
2,500,315 |
|
349,029 |
Total assets |
6,453,665 |
|
6,523,028 |
|
910,579 |
|
|
|
|
|
|
Liabilities, Mezzanine Equity and Shareholders' |
|
|
|
|
|
Current liabilities |
|
|
|
|
|
Amount due to related parties |
10,616 |
|
9,834 |
|
1,373 |
Insurance premium payables |
537,344 |
|
608,994 |
|
85,012 |
Accrued expenses and other current liabilities |
704,035 |
|
724,189 |
|
101,093 |
Short-term loans |
198,373 |
|
63,000 |
|
8,794 |
Current lease liabilities |
34,573 |
|
11,866 |
|
1,656 |
Total current liabilities |
1,484,941 |
|
1,417,883 |
|
197,928 |
Non-current liabilities |
|
|
|
|
|
Non-current lease liabilities |
10,971 |
|
4,948 |
|
691 |
Deferred tax liabilities |
84,185 |
|
87,602 |
|
12,229 |
Total non-current liabilities |
95,156 |
|
92,550 |
|
12,920 |
Total liabilities |
1,580,097 |
|
1,510,433 |
|
210,848 |
|
|
|
|
|
|
Mezzanine Equit y |
|
|
|
|
|
Redeemable non-controlling interests |
76,133 |
|
- |
|
- |
|
|
|
|
|
|
Shareholders' equity |
|
|
|
|
|
Class A ordinary shares |
112 |
|
114 |
|
16 |
Class B ordinary shares |
27 |
|
27 |
|
4 |
|
(15) |
|
(15) |
|
(2) |
Additional paid-in capital |
6,832,214 |
|
6,847,516 |
|
955,876 |
Accumulated other comprehensive income |
159,550 |
|
111,052 |
|
15,502 |
Accumulated deficit |
(2,194,453) |
|
(1,946,099) |
|
(271,665) |
Total shareholders' equity |
4,797,435 |
|
5,012,595 |
|
699,731 |
Total liabilities, mezzanine equity and shareholders' equity |
6,453,665 |
|
6,523,028 |
|
910,579 |
|
||||||||||||||
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME |
||||||||||||||
(All amounts in thousands, except for share and per share data, or otherwise noted) |
||||||||||||||
|
||||||||||||||
|
|
For the Three Months Ended |
|
For the Six Months Ended |
||||||||||
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
RMB |
|
RMB |
|
RMB |
|
USD |
|
RMB |
|
RMB |
|
USD |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating revenue, net |
|
676,156 |
|
753,694 |
|
837,959 |
|
116,975 |
|
1,380,856 |
|
1,591,653 |
|
222,186 |
Operating costs and expenses (i) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating costs |
|
(319,101) |
|
(374,218) |
|
(416,493) |
|
(58,140) |
|
(650,344) |
|
(790,711) |
|
(110,379) |
Sales and marketing expenses |
|
(157,413) |
|
(172,396) |
|
(198,785) |
|
(27,749) |
|
(339,559) |
|
(371,181) |
|
(51,815) |
General and administrative expenses |
|
(93,978) |
|
(74,943) |
|
(73,400) |
|
(10,246) |
|
(182,939) |
|
(148,343) |
|
(20,708) |
Research and development expenses |
|
(53,300) |
|
(56,244) |
|
(51,945) |
|
(7,251) |
|
(109,286) |
|
(108,189) |
|
(15,103) |
Total operating costs and expenses |
|
(623,792) |
|
(677,801) |
|
(740,623) |
|
(103,386) |
|
(1,282,128) |
|
(1,418,424) |
|
(198,005) |
Operating profit |
|
52,364 |
|
75,893 |
|
97,336 |
|
13,589 |
|
98,728 |
|
173,229 |
|
24,181 |
Other income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income |
|
37,510 |
|
33,814 |
|
29,534 |
|
4,123 |
|
77,314 |
|
63,348 |
|
8,843 |
Foreign currency exchange (loss)/gain |
|
(444) |
|
(2,103) |
|
2,656 |
|
371 |
|
1,070 |
|
553 |
|
77 |
Others, net |
|
1,300 |
|
9,979 |
|
7,842 |
|
1,095 |
|
2,763 |
|
17,821 |
|
2,488 |
Profit before income tax |
|
90,730 |
|
117,583 |
|
137,368 |
|
19,178 |
|
179,875 |
|
254,951 |
|
35,589 |
Income tax (expense)/benefit |
|
(7,026) |
|
(13,328) |
|
2,852 |
|
398 |
|
(15,614) |
|
(10,476) |
|
(1,462) |
Net profit |
|
83,704 |
|
104,255 |
|
140,220 |
|
19,576 |
|
164,261 |
|
244,475 |
|
34,127 |
Net (loss)/profit attributable to mezzanine equity classified as non- |
|
(4,586) |
|
(3,940) |
|
61 |
|
9 |
|
(4,661) |
|
(3,879) |
|
(541) |
Net profit attributable to ordinary shareholders |
|
88,290 |
|
108,195 |
|
140,159 |
|
19,567 |
|
168,922 |
|
248,354 |
|
34,668 |
Other comprehensive income: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency translation adjustment, net of tax |
|
13,497 |
|
(14,056) |
|
(33,283) |
|
(4,646) |
|
38,640 |
|
(47,339) |
|
(6,608) |
Unrealized gain/(loss) on available for sale investments, net of tax |
|
- |
|
17,612 |
|
(18,771) |
|
(2,620) |
|
- |
|
(1,159) |
|
(162) |
Total comprehensive income |
|
97,201 |
|
107,811 |
|
88,166 |
|
12,310 |
|
202,901 |
|
195,977 |
|
27,357 |
Total comprehensive (loss)/profit attributable to mezzanine equity |
|
(4,586) |
|
(3,940) |
|
61 |
|
9 |
|
(4,661) |
|
(3,879) |
|
(541) |
Total comprehensive income attributable to ordinary shareholders |
|
101,787 |
|
111,751 |
|
88,105 |
|
12,301 |
|
207,562 |
|
199,856 |
|
27,898 |
Weighted average number of ordinary shares used in computing |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
3,660,589,600 |
|
3,620,380,862 |
|
3,608,253,358 |
|
3,608,253,358 |
|
3,678,604,386 |
|
3,614,283,609 |
|
3,614,283,609 |
Diluted |
|
3,734,346,444 |
|
3,711,999,000 |
|
3,711,084,352 |
|
3,711,084,352 |
|
3,745,404,276 |
|
3,711,508,175 |
|
3,711,508,175 |
Net profit per share attributable to ordinary shareholders |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
0.02 |
|
0.03 |
|
0.04 |
|
0.01 |
|
0.05 |
|
0.07 |
|
0.01 |
Diluted |
|
0.02 |
|
0.03 |
|
0.04 |
|
0.01 |
|
0.05 |
|
0.07 |
|
0.01 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(i) Share-based compensation expenses are included in the operating costs and expenses as follows. |
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended |
|
For the Six Months Ended |
||||||||||
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
RMB |
|
RMB |
|
RMB |
|
USD |
|
RMB |
|
RMB |
|
USD |
Sales and marketing expenses |
|
(1,320) |
|
(1,899) |
|
(1,949) |
|
(272) |
|
(3,140) |
|
(3,848) |
|
(537) |
General and administrative expenses |
|
(16,285) |
|
(15,527) |
|
(11,899) |
|
(1,661) |
|
(30,612) |
|
(27,426) |
|
(3,829) |
Research and development expenses |
|
(2,600) |
|
(2,501) |
|
(994) |
|
(139) |
|
(5,583) |
|
(3,495) |
|
(488) |
Total |
|
(20,205) |
|
(19,927) |
|
(14,842) |
|
(2,072) |
|
(39,335) |
|
(34,769) |
|
(4,854) |
|
||||||||||||||
RECONCILIATIONS OF GAAP AND NON-GAAP RESULTS |
||||||||||||||
(All amounts in thousands, unless otherwise noted) |
||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended |
|
For the Six Months Ended |
||||||||||
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
RMB |
|
RMB |
|
RMB |
|
USD |
|
RMB |
|
RMB |
|
USD |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net profit attributable to the Company's ordinary |
|
88,290 |
|
108,195 |
|
140,159 |
|
19,567 |
|
168,922 |
|
248,354 |
|
34,668 |
Add: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Share-based compensation expense attributable to the |
|
20,015 |
|
19,750 |
|
14,144 |
|
1,974 |
|
39,274 |
|
33,894 |
|
4,731 |
Foreign currency exchange loss/(gain) |
|
444 |
|
2,103 |
|
(2,656) |
|
(371) |
|
(1,070) |
|
(553) |
|
(77) |
Adjusted net profit attributable to the Company's ordinary |
|
108,749 |
|
130,048 |
|
151,647 |
|
21,170 |
|
207,126 |
|
281,695 |
|
39,322 |
View original content:https://www.prnewswire.com/news-releases/waterdrop-inc-announces-second-quarter-2025-unaudited-financial-results-and-a-cash-dividend-302546375.html
SOURCE